Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial

摘要: Despite several introduced preventive modalities, cisplatin nephrotoxicity remains a clinical problem. Some in vitro and vivo studies have addressed the protective effects of silymarin against nephrotoxicity. This study evaluated administration on as first human study. During this pilot, randomized, double-blinded, placebo-controlled trial, effect oral 420 mg daily three divided doses starting 24–48 h before initiation infusion continuing to end 21-day cisplatin-containing chemotherapy courses cisplatin-induced renal electrolytes wasting kidney function were assessed. Cisplatin-associated acute injury (AKI) occurred 8% patients. Urine neutrophil gelatinase-associated lipocalin urine creatinine ratio (NGAL/Cr) urinary magnesium potassium increased significantly after both groups. Significant positive correlation was found between cumulative dose NGAL/Cr infusion. Incidence AKI magnitude did not differ placebo No adverse reaction reported by administration. Prophylactic conventional form tablets could prevent electrolyte or impairment. Copyright © 2015 John Wiley & Sons, Ltd.